These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8410074)

  • 61. Schwann cells sense and control acetylcholine spillover at the neuromuscular junction by α7 nicotinic receptors and butyrylcholinesterase.
    Petrov KA; Girard E; Nikitashina AD; Colasante C; Bernard V; Nurullin L; Leroy J; Samigullin D; Colak O; Nikolsky E; Plaud B; Krejci E
    J Neurosci; 2014 Sep; 34(36):11870-83. PubMed ID: 25186736
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The role of acetylcholine receptor antibodies in myasthenia gravis.
    Appel SH; Elias SB; Chauvin P
    Fed Proc; 1979 Sep; 38(10):2381-5. PubMed ID: 478014
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.
    Besinger UA; Toyka KV; Hömberg M; Heininger K; Hohlfeld R; Fateh-Moghadam A
    Neurology; 1983 Oct; 33(10):1316-21. PubMed ID: 6684226
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Patient-specific anti=acetylcholine receptor antibody patterns in myasthenia gravis.
    Savage-Marengo T; Harrison R; Lunt GG; Behan PO
    J Neurol Neurosurg Psychiatry; 1980 Apr; 43(4):316-20. PubMed ID: 7373331
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs.
    Cetin H; Webster R; Liu WW; Nagaishi A; Koneczny I; Zimprich F; Maxwell S; Cossins J; Beeson D; Vincent A
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):526-532. PubMed ID: 32165373
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Myasthenia gravis and myasthenic syndromes.
    Engel AG
    Ann Neurol; 1984 Nov; 16(5):519-34. PubMed ID: 6095730
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A modified assay for antibody against the nicotinic acetylcholine receptor in myasthenia gravis.
    Dwyer DS; Bradley RJ; Oh SJ; Kemp GE
    Clin Exp Immunol; 1979 Sep; 37(3):448-51. PubMed ID: 509779
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Stabilization of acetylcholine receptors at neuromuscular junctions: analysis by specific antibodies.
    Stanley EF; Drachman DB
    Ann N Y Acad Sci; 1987; 505():121-32. PubMed ID: 3479925
    [No Abstract]   [Full Text] [Related]  

  • 70. Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins.
    Appel SH; Anwyl R; McAdams MW; Elias S
    Proc Natl Acad Sci U S A; 1977 May; 74(5):2130-4. PubMed ID: 266734
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Antibody against synthetic peptide corresponding to alpha-subunit residues 128-142 of nicotinic acetylcholine receptor (AChR): the significance in myasthenia gravis (MG)].
    Shibuya N; Kanazawa H; Uyemura K
    Rinsho Shinkeigaku; 1988 Mar; 28(3):315-9. PubMed ID: 3402139
    [No Abstract]   [Full Text] [Related]  

  • 72. The auto-antigen repertoire in myasthenia gravis.
    Vrolix K; Fraussen J; Molenaar PC; Losen M; Somers V; Stinissen P; De Baets MH; Martínez-Martínez P
    Autoimmunity; 2010 Aug; 43(5-6):380-400. PubMed ID: 20380581
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with herpes simplex virus.
    Schwimmbeck PL; Dyrberg T; Drachman DB; Oldstone MB
    J Clin Invest; 1989 Oct; 84(4):1174-80. PubMed ID: 2551924
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The immunopathology of myasthenia gravis.
    Lennon VA
    Hum Pathol; 1978 Sep; 9(5):541-51. PubMed ID: 309428
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability.
    Vernino S; Lennon VA
    Muscle Nerve; 2002 Nov; 26(5):702-7. PubMed ID: 12402293
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunological and pharmacological heterogeneity of alpha-bungarotoxin binding sites extracted from TE671 cells.
    Walker R; Vincent A; Newsom-Davis J
    J Neuroimmunol; 1988 Aug; 19(1-2):149-57. PubMed ID: 3397405
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunopathology of acetylcholine receptors in myasthenia gravis.
    Seybold ME; Lindstrom JM
    Springer Semin Immunopathol; 1982; 5(4):389-412. PubMed ID: 6761884
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis.
    Aharonov A; Abramsky O; Tarrab-Hazdai R; Fuchs S
    Lancet; 1975 Aug; 2(7930):340-2. PubMed ID: 51144
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of antibodies in myasthenia gravis.
    De Baets M; Stassen MH
    J Neurol Sci; 2002 Oct; 202(1-2):5-11. PubMed ID: 12220686
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acetylcholine receptor antibody characteristics in myasthenia gravis. III. Patients with low anti-AChR antibody levels.
    Vincent A; Newsom-Davis J
    Clin Exp Immunol; 1985 Jun; 60(3):631-6. PubMed ID: 2410169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.